Health · Pharma & Biotech · 11 hrs ago

FDA rejects Capricor’s Duchenne therapy for a second time

FDA rejects Capricor’s Duchenne therapy for a second time

The FDA rejected Capricor Therapeutics’ deramiocel for a second time on Friday.

The cell therapy was developed for people with Duchenne muscular dystrophy, a progressive disease that weakens muscles.

Capricor had narrowed the group of patients it sought approval to treat, but the FDA still cited significant issues with the trial.

The intended patients were teenagers and young men who had already lost the ability to walk and have few treatment options.

In two randomized trials, deramiocel did not show it could prevent heart failure or preserve arm muscle function.

The rejection means the therapy cannot reach the market for these patients, and no further steps were specified.

2 sources

Related